BB Biotech AG (BION) - Total Assets
Based on the latest financial reports, BB Biotech AG (BION) holds total assets worth CHF3.09 Billion CHF (≈ $3.91 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BB Biotech AG - Total Assets Trend (2003–2025)
This chart illustrates how BB Biotech AG's total assets have evolved over time, based on quarterly financial data. Also see BB Biotech AG (BION) total market value for the company's overall valuation and market capitalisation.
BB Biotech AG - Asset Composition Analysis
Current Asset Composition (December 2025)
BB Biotech AG's total assets of CHF3.09 Billion consist of 3.8% current assets and 96.2% non-current assets. Review total liabilities of BB Biotech AG to assess the company's total debt and financial obligations.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 3.5% |
| Accounts Receivable | CHF5.51 Million | 0.2% |
| Inventory | CHF0.00 | 0.0% |
| Property, Plant & Equipment | CHF0.00 | 0.0% |
| Intangible Assets | CHF0.00 | 0.0% |
| Goodwill | CHF0.00 | 0.0% |
Asset Composition Trend (2003–2025)
This chart illustrates how BB Biotech AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See BB Biotech AG share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BB Biotech AG's current assets represent 3.8% of total assets in 2025, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 3.5% of total assets in 2025, up from 0.0% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
BB Biotech AG Competitors by Total Assets
Key competitors of BB Biotech AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
BB Biotech AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 631.62 | 0.01 | 52.43 |
| Quick Ratio | 631.62 | 0.01 | 52.43 |
| Cash Ratio | 0.00 | 0.01 | 0.00 |
| Working Capital | CHF2.31 Billion | CHF-274.99 Million | CHF3.89 Billion |
BB Biotech AG - Advanced Valuation Insights
This section examines the relationship between BB Biotech AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.95 |
| Latest Market Cap to Assets Ratio | 1.05 |
| Asset Growth Rate (YoY) | 15.7% |
| Total Assets | CHF2.79 Billion |
| Market Capitalization | $2.93 Billion USD |
Valuation Analysis
Above Book Valuation: The market values BB Biotech AG's assets above their book value (1.05x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: BB Biotech AG's assets grew by 15.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BB Biotech AG (2003–2025)
The table below shows the annual total assets of BB Biotech AG from 2003 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CHF2.79 Billion ≈ $3.52 Billion |
+15.72% |
| 2024-12-31 | CHF2.41 Billion ≈ $3.04 Billion |
-8.71% |
| 2023-12-31 | CHF2.64 Billion ≈ $3.33 Billion |
-13.63% |
| 2022-12-31 | CHF3.05 Billion ≈ $3.86 Billion |
-16.21% |
| 2021-12-31 | CHF3.64 Billion ≈ $4.61 Billion |
-8.05% |
| 2020-12-31 | CHF3.96 Billion ≈ $5.01 Billion |
+11.49% |
| 2019-12-31 | CHF3.55 Billion ≈ $4.49 Billion |
+15.15% |
| 2018-12-31 | CHF3.09 Billion ≈ $3.90 Billion |
-15.15% |
| 2017-12-31 | CHF3.64 Billion ≈ $4.60 Billion |
+12.76% |
| 2016-12-31 | CHF3.23 Billion ≈ $4.08 Billion |
-22.14% |
| 2015-12-31 | CHF4.14 Billion ≈ $5.24 Billion |
+17.29% |
| 2014-12-31 | CHF3.53 Billion ≈ $4.47 Billion |
+59.79% |
| 2013-12-31 | CHF2.21 Billion ≈ $2.80 Billion |
+60.91% |
| 2012-12-31 | CHF1.37 Billion ≈ $1.74 Billion |
+19.31% |
| 2011-12-31 | CHF1.15 Billion ≈ $1.46 Billion |
-16.37% |
| 2010-12-31 | CHF1.38 Billion ≈ $1.74 Billion |
-9.46% |
| 2009-12-31 | CHF1.52 Billion ≈ $1.92 Billion |
-6.07% |
| 2008-12-31 | CHF1.62 Billion ≈ $2.05 Billion |
-22.04% |
| 2007-12-31 | CHF2.08 Billion ≈ $2.63 Billion |
-18.67% |
| 2006-12-31 | CHF2.55 Billion ≈ $3.23 Billion |
+2.22% |
| 2005-12-31 | CHF2.50 Billion ≈ $3.16 Billion |
+30.25% |
| 2004-12-31 | CHF1.92 Billion ≈ $2.42 Billion |
-3.26% |
| 2003-12-31 | CHF1.98 Billion ≈ $2.51 Billion |
-- |
About BB Biotech AG
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domicile… Read more